OcuMedic, Inc.

3:30 PM - 3:45 PM, Wednesday, June 5, 2019 ・ Theater 2
OcuMedic’s technology: Timed Drug Delivery to the Eye via a Contact Lens/Clear Corneal Bandage with 7 Day wear.The technology rests on 10 issued patents, and a recent Freedom to Operate (FTO) opinion. Efficacy has been proven in an animal model. The intellectual property teaches a novel therapeutic contact lens with memory capable of controlled release of first line ophthalmic agents, both anti-inflammatory and antibiotic. The technology has been developed for the most common and widely used contact lens material silicon hydrogel, (SiHy). The technology is also a platform technology and has been tested for a wide range of ten (10) other drugs as well as molecules to enhance lens comfort and treat dry eye. It has been shown that the extension of release has a strong dependence on mimicking biological recognition in the design exploiting the chemical diversity and amounts of monomers in relation to the drug. OcuMedic can literally-DIAL IN THE RELEASE OF DRUG FROM THE LENS OVER Time
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
OMoo2 Delivery of bromfenac inflamation & Pain for pre & post Cataract surgery / LASIK surgery
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
President & CEO
OcuMedics, Inc.